Merck Can't Duck Jury Award In Fosamax Bellwether Suit

Law360, New York (July 1, 2013, 7:43 PM EDT) -- A New York federal judge on Monday denied Merck & Co. Inc.'s attempt to wipe out a $285,000 plaintiff verdict in a bellwether trial in multidistrict litigation claiming the bone drug Fosamax causes jaw deterioration, rejecting its argument that its warning was adequate.

Judge John Keenan rejected a motion for judgment as a matter of law filed by Merck challenging a jury's determination in February that the drugmaker failed to adequately warn plaintiff Rhoda Scheinberg that using Fosamax could cause her to develop osteonecrosis of the jaw....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In Re: Fosamax Products Liability Litigation


Case Number

1:06-md-01789

Court

New York Southern

Nature of Suit

Judge

John F. Keenan

Date Filed

August 18, 2006


Case Title

Scheinberg v. Merck & Co., Inc.


Case Number

1:08-cv-04119

Court

New York Southern

Nature of Suit

Personal Inj. Prod. Liability

Judge

John F. Keenan

Date Filed

May 1, 2008

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.